ArticleTranslational pediatrics2026
Irinotecan plus temozolomide for pediatric relapsed or refractory solid tumors: a retrospective cohort study.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Relapsed or refractory pediatric solid tumors carry a poor prognosis, and effective salvage therapies are limited. The combination of irinotecan and temozolomide (IT) has shown promise in early studies, but real‑world data in Chinese pediatric populations are lacking. This study aims to evaluate the efficacy and safety of the IT regimen in children with recurrent or refractory solid tumors. Methods: This single‑center retrospective cohort study included 86 pediatric patients with relapsed or refractory malignant solid tumors treated at Beijing Jingdu Children's Hospital (March 2021-March 2025). Inclusion criteria were pathologically confirmed recurrence/progression, adequate organ function, and no prior IT therapy. Patients received irinotecan (50 mg/m Results: Of 86 patients (median age 7 years, range 1-18 years; 52 neuroblastoma), the median number of prior chemotherapy lines was 3 (range 1-7). ORR was 23.3% [95% confidence interval (CI): 15.1-33.6%] and DCR 52.4% (95% CI: 41.3-63.3%). For neuroblastoma (n=52), ORR was 31.0% (95% CI: 19.5-44.5%) and DCR 67.3% (95% CI: 53.7-78.8%). Median PFS was 5.5 months (95% CI: 3.8-8.1) and median OS 9.8 months (95% CI: 6.5-14.2). The 1‑year OS rate was 36.8% (95% CI: 27.5-49.4%) and 1‑year PFS rate 22.4% (95% CI: 14.7-34.4%). Grade III-IV adverse events included neutropenia (25.2% of cycles), thrombocytopenia (26.0%), diarrhea (3.6%), and liver dysfunction (4.0%). No treatment‑related deaths occurred. Conclusions: The IT regimen demonstrates clinical activity and was found to be tolerable in this cohort. These findings are hypothesis‑generating and warrant confirmation in prospective controlled studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.